Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WD-01 CAR-T in Metastatic Colorectal Cancer
NCT06675513Phase 1Suspended
- Sponsor
- Wondercel Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WD-01 in colorectal cancer (CRC), sponsored by Wondercel Therapeutics. Primary endpoints: Maximum Tolerated Dose at 1 month, Dose-Limiting Toxicities at 1 month and 1 more. Started May 2025; status: suspended.
02
Drugs
WD-01
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06675513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675513.